Universal Health Services (UHS) investor relations material

Financial performance and guidance

• Q2 saw rebounded volumes and effective cost control in both acute and behavioral segments, with revised full-year 2026 guidance projecting 3% EBITDA growth and 6% EPS growth.

• Closed the Talkspace acquisition and completed a $1.1 billion bond issuance, supporting future growth.

• Acute adjusted admissions target revised to a 2% midpoint for 2026, reflecting historical norms and a soft Q1.

• Ramp-up of new facilities, especially Cedar Hill and West Henderson, is key to volume growth, with West Henderson achieving profitability rapidly.

• Exchange headwind for 2026 increased to $85 million, with $50 million expected in the second half, and similar pressure anticipated for 2027.

Market and operational developments

• Cedar Hill facility, built with DC government support, is experiencing strong emergency volumes but slower elective growth due to limited local physician infrastructure.

• Physician recruitment and local office expansion are ongoing to boost elective procedures at Cedar Hill.

• West Henderson’s rapid ramp-up reflects strong market demand and population growth in southeast Las Vegas, with some volume shift from legacy facilities.

• Las Vegas market rebounded in 2025 after a softer year, aided by diversified local economy and tourism recovery.

Payer mix and policy environment

• Managed Medicaid volumes declined modestly, with slight increases in Medicare and managed Medicare; commercial volumes stable outside exchanges.

• Medicaid work requirements, effective 2027, could cause up to 4% disenrollment, but impact depends on state implementation and medical frailty exemptions.

• Intake staff are trained to help uninsured patients access coverage, including Medicaid, COBRA, or county programs.

• Statutory SDP limits will have minimal impact in 2027, with most cuts ($500 million over five years) starting in 2028; political changes could affect timing.

• Proposed 2027 OPPS rule could increase outpatient Medicare reimbursement by about 8%, benefiting for-profit providers with limited 340B exposure.